diseases

Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies

Source Node:
Time Stamp: February 7, 2024 10:49 AM - Modified On: February 7, 2024 - Published By:
Source Cluster:
Republished By Plato

Legislation Puts Renewed Focus on Next-Generation NK Cell Therapies New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses. The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals” in a plenary session paving the way for certain next generation NK Cell Therapy companies to recognized as a licensed

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

HealthCare AI: The Unavoidable Revolution in Modern Medicine

Source Node:
Time Stamp: October 5, 2023 3:39 PM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

By Eric Greenberg www.linkedin.com/in/ericabg In the evolving landscape of medical technology, there's one force that stands head and shoulders above the rest, promising a seismic shift in the very ethos of healthcare delivery: Artificial Intelligence (AI). As a seasoned technology and banking analyst, it is my considered opinion that Healthcare AI isn't just a trend or a buzzword. It’s the very future of medicine, poised to reshape everything we know about patient care, disease diagnosis, and medical research. To begin with, the economic implications of integrating AI in healthcare are

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

How will artificial intelligence change the lives of all of us?

Source Node:
Time Stamp: January 19, 2023 8:12 AM - Modified On: January 19, 2023 - Published By:
Source Cluster:
Republished By Plato

Artificial intelligence (AI) is rapidly changing the way we live, work and play. As intelligent machines learn, think and reason like humans, AI will change the way companies operate, the way people interact with technology, and even our perception of our own humanity. Artificial intelligence is promised to revolutionize almost all sectors from gambling to traffic, make life easier for consumers, offer organizations ways to utilize data and create completely new job opportunities. The gambling industry is a good example The gambling industry is one of the sectors where the

New Lab Studies Suggest InBios COVID-19 POC Antigen Detection Test Will Detect Delta Variant

Source Node: https://www.prweb.com/releases/new_lab_studies_suggest_inbios_covid_19_poc_antigen_detection_test_will_detect_delta_variant/prweb18146251.htm
Time Stamp: August 22, 2021 9:00 AM - Modified On: August 22, 2021 - Published By:
Source Cluster:
Republished By Plato

SCoV-2 Ag Detect Rapid Test SEATTLE (PRWEB) August 22, 2021 InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that laboratory studies suggest its SCoV-2 Ag Detect Rapid Test will detect the Delta variant (lineage B.1.617.2), which is responsible for a rapid rise of infections and deaths in the US and around the world. Initial studies suggest that InBios’ point-of-care antigen test will detect the Delta variant at rates similar to the USA-WA1-2020 isolate that was used to develop the assay. “Having a rapid

How to Restore Your Faith in Government

Source Node: https://www.bitcoinmarketjournal.com/how-to-restore-your-faith-in-government/
Time Stamp: August 18, 2020 5:47 PM - Modified On: May 21, 2021 - Published By:
Source Cluster:
Republished By Plato

Images courtesy of MIT Video Productions Here’s the announcement of the new blockchain education program with the Massachusetts state government. It’s a big deal. We have a vision for where this kind of partnership can go, when governments begin educating themselves on the power of bitcoin and blockchain. That vision can be summed up in two words: Kendall Square. Kendall Square, then. The Kendall Square neighborhood lies next to the Massachusetts Institute of Technology, stretching along the Charles River that separates Cambridge from Boston. (Here’s a map.) Although you’d think